Online inquiry

IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3702MR)

This product GTTS-WQ3702MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3702MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15612MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ5586MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ7720MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ7252MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ6624MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ262MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ8584MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ9513MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA J2898A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW